Department of Physiology, Faculty of Basic Medical Sciences, University of Uyo, Uyo, Akwa-Ibom State, Nigeria.
Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Nigeria.
Biomed Pharmacother. 2018 May;101:792-797. doi: 10.1016/j.biopha.2018.03.001. Epub 2018 Mar 22.
Nitric oxide (NO) is major endothelial relaxing factor and reduction in its bioavailabilty has been linked to hypertension. Furthermore, high lipid content is a strong risk factor predisposing to cardiovascular diseases. The principal focus of this study was to investigate the effect of blockade of nitric oxide synthase (NOS) on serum lipid content in rats. Male Wistar rats (150-170 g, n = 15) were randomly divided into two groups designated control (n = 5), and L-Name group (n = 10) and were gavage with distilled water and 60 mg/kg of L-NAME respectively daily for three weeks. After 3 weeks, the L-NAME group was sub-divided into two sub-groups (n = 5 each): L-NAME (60 mg/kg of L-NAME), and L-NAME plus ramipril (LR) (60 mg/kg of L-NAME plus 20 mg/kg of ramipril) and were treated daily for another three weeks. The blood pressure (BP) of the conscious rats was measured by tail-cuff method at the onset, at the third and at the sixth weeks of the experiment; while serum lipid contents and NO were measured at the third and sixth weeks. At the end of the experiment blood sample was drawn by ocular puncture for evaluation of lipid profile and NO, and the animals were later euthanized by overdose of anaesthesia. Data were analyzed using ANOVA at p < 0.05. There was a significant increase in BP, triglyceride, total cholesterol, low density lipoprotein-cholesterol, and atherogenic indices in L-NAME group compared to the control and LR group (p < 0.05); NO and high density lipoprotein-cholesterol was significant lower in the L-NAME group compared to control and LR (p < 0.05). In conclusion, reduction in NO bioavailability alters lipid metabolism, which was rectified by ramipril.
一氧化氮（NO）是主要的内皮舒张因子，其生物利用度的降低与高血压有关。此外，高脂质含量是导致心血管疾病的一个强有力的危险因素。本研究的主要目的是研究一氧化氮合酶（NOS）抑制剂对大鼠血清脂质含量的影响。雄性 Wistar 大鼠（150-170g，n=15）随机分为两组，对照组（n=5）和 L-Name 组（n=10），分别给予蒸馏水和 60mg/kg 的 L-NAME 灌胃，每天一次，持续 3 周。3 周后，L-NAME 组再分为两组（n=5 只/组）：L-NAME（60mg/kg 的 L-NAME）和 L-NAME 加雷米普利（LR）（60mg/kg 的 L-NAME 加 20mg/kg 的雷米普利），并分别治疗 3 周。通过尾套法在实验开始时、第 3 周和第 6 周测量清醒大鼠的血压（BP）；在第 3 周和第 6 周测量血清脂质含量和 NO。实验结束时，通过眼部穿刺采血评估血脂谱和 NO，然后过量麻醉处死动物。数据采用 ANOVA 分析，p<0.05 为差异有统计学意义。与对照组和 LR 组相比，L-NAME 组的 BP、三酰甘油、总胆固醇、低密度脂蛋白胆固醇和致动脉粥样硬化指数显著升高（p<0.05）；L-NAME 组的 NO 和高密度脂蛋白胆固醇明显低于对照组和 LR 组（p<0.05）。结论：NO 生物利用度降低会改变脂质代谢，雷米普利可纠正这种改变。
